Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in Prevention of Allergen-Induced Airway Obstruction
NCT00781443Phase 2Completed
- Sponsor
- Genentech
- Start
- Dec 2008
- Primary completion
- Nov 2009
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial in allergic asthma comparing Lebrikizumab with Placebo (2 arms). Primary endpoint: Late Asthmatic Response at Day 92. Started Dec 2008; status: completed.
02
Drugs
lebrikizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT00781443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00781443.